# Themasap Khan

> Themasap Khan is a Series A investor at Luma Group backing Health Care and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Luma Group](https://shizune.co/investors/profile/luma-group-1729)
- Location: Silicon Valley, United States
- Total investments: 2
- Last investment: Dec 2025
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/themasap/
- X (Twitter): https://twitter.com/themasap
- Website: https://x.com/themasap
- Facebook: https://www.facebook.com/Themasap

Themasap Khan is a Series A investor at Luma Group in Silicon Valley focused on Health Care and Biotechnology. Themasap A. Khan is based out of New York, New York, and is the Co-Founder and Partner at Luma Group and Board of Director at Aeovian Pharmaceuticals. Themasap previously served as the Senior Advisor at Civilization Ventures. Themasap A. Khan attended New York University. Themasap A. Khan has received National Science Foundation GraduateFellowship award.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Biopharma | 1 | 50% |
| Pharmaceutical | 1 | 50% |
| Health Diagnostics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M | Series B | Dec 16, 2025 |  |
| Curve Biosciences | Curve Biosciences is a biotechnology company focused on enhancing chronic disease care through precision medicine. With a team led by experts such as Nathan Hunkapiller, PhD, as Chief Scientific Officer, and Chuba Oyolu, PhD, as Chief Technology Officer, the company is at the forefront of research and development in the biotech field. CurveBiosciences aims to leverage scientific advancements to provide targeted solutions for chronic diseases, emphasizing the importance of precision in treatment approaches. The company operates within the biotechnology industry and is dedicated to improving patient outcomes through innovative research. | $40M | Series A | Oct 29, 2025 |  |

2 of 2 investments shown.

## Co-investors
- [The TSC Alliance Endowment Fund](https://shizune.co/investors/profile/the-tsc-alliance-endowment-fund) — VC Fund, 3 deals together
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 1 deal together
- [Civilization Ventures](https://shizune.co/investors/profile/civilization-ventures) — VC Fund, 1 deal together
- [CTI Life Sciences Fund](https://shizune.co/investors/profile/cti-life-sciences-fund-2) — VC Fund, 1 deal together
- [First Spark Ventures](https://shizune.co/investors/profile/first-spark-ventures) — VC Fund, 1 deal together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 1 deal together

## About Luma Group

VC Fund · New York, United States

Luma Group is an investment firm focused on the intersection of technology-driven life sciences and healthcare companies.

1 contacts available at Luma Group.

| Name | Title | Profile |
| --- | --- | --- |
| Themasap Khan | Co-Founder and Partner | https://shizune.co/investors/profile/themasap-khan |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Themasap Khan invest in?

Themasap Khan invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Themasap Khan last invest?

The most recent investment recorded for Themasap Khan closed in Dec 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co